Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer - sprookjes - yvandenbroek - TriplyDB

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

http://www.wikidata.org/entity/Q34989083

about

The PI3K/Akt Pathway in Tumors of Endocrine Tissues World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels.Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box.Influence of biospecimen variables on proteomic biomarkers in breast cancer When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique.Predictive and prognostic factors.c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands.Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer Rapid two-temperature formalin fixation.MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.Post-translational modifications of nuclear receptors and human disease Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion.An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Ki67 and proliferation in breast cancer.

P2860

Q26770404-3E3B147F-8185-4B1A-8805-04C52F1515F8 Q26827259-28F37077-6ED6-4A12-807C-2D09C7B6E556 Q26851269-BFC08626-D4F8-4A54-8C57-68A4C4E0F259 Q30358990-F536A103-11D9-433A-AA09-C281CCC79AAB Q33587930-EC59765A-53B3-4559-B4D5-662D36830F35 Q33649620-C3E178C8-F24B-48FB-908B-B5CBE9643991 Q33680890-E8E91DF6-D82C-4ECB-A721-2550680E15D2 Q33827011-E9B07E59-E2AA-4C61-927A-252246E9BB1B Q33850616-77F62514-A876-4032-B58E-08D065C8A4D8 Q33850627-79017AB4-34A4-4218-807B-C6FF563ABFBE Q33876854-635836EC-B2F3-42FF-B77A-722FD882F169 Q33957206-8CAE1197-6B67-4048-901C-33A6F087D104 Q34377983-E0243996-3634-476A-B1BC-53A1F4E7E23C Q34423453-504FED78-0B81-44CA-96A6-36D9DAF256A9 Q34478359-C989AD2F-21B9-4A57-95BA-0076031B131E Q34515619-C20852AE-5363-497E-8E7D-80C498FA2BC1 Q34542434-7B21D901-8027-4079-8EE2-44DB6C7EE4D1 Q34562672-03FE8552-198D-4D97-B075-2C5169AEB0BA Q34699904-3FB0EC4A-7399-46E1-8DC8-A503AFE21E0A Q35100621-D7B61F73-D55D-4F2E-8D41-93B9825576C2 Q35113027-D77DD264-2651-4CBB-9AAA-17583631E561 Q35131931-EF6993EB-D0AF-43DC-A9F7-28EE56CA43E6 Q35552069-B98CA2FC-1853-4765-891B-531B9CEAC0A8 Q35559032-D4B8EDDE-1A9F-4F3A-8E4F-C06E59B52415 Q35574950-8CFB54E7-092A-4B43-BD8E-5F3795188F6A Q35663802-DA337367-45EC-4209-A3AA-BE94320C4750 Q35842790-D27AB50F-F4CF-4679-8078-BE1EC4D3D146 Q36199762-BDA1C470-3EB1-4401-8B1E-E6655000E837 Q36223407-35E4EBCD-A339-49CC-B062-87A3B2EA1520 Q36444728-D1B87BDD-9AB6-468A-87F2-397B020700B4 Q36510571-A9FF9032-65D6-4807-8817-17E1D0D2775C Q36610246-DE4EA962-A38C-44DA-9EF7-F0592B3F8936 Q36681892-CBF79024-D768-4AE4-88F7-6982964D5D35 Q36758456-23FE8B7C-89BF-4FB7-886F-D746DAE344EA Q36929331-5631CEB3-9FA6-4EF5-9BD4-674D9E266CF3 Q37205832-CF268B29-D452-4C49-953E-38A8F609CE92 Q37494320-B16EE5CC-EF9C-45F9-901C-4EBACE027A59 Q37600497-41149153-76AB-410E-B6ED-7B35C91C2DC2 Q38042638-3122A455-59BB-4E19-9EA3-2B720A83D1E9 Q38084286-4ABA88BD-2C4E-498F-8CBA-DC35B7FA651E

P2860

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

http://www.wikidata.org/entity/Q34989083

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Extreme loss of immunoreactive ...... ation of primary breast cancer

@ast

Extreme loss of immunoreactive ...... ation of primary breast cancer

@en

Extreme loss of immunoreactive ...... ation of primary breast cancer

@nl

type

label

Extreme loss of immunoreactive ...... ation of primary breast cancer

@ast

Extreme loss of immunoreactive ...... ation of primary breast cancer

@en

Extreme loss of immunoreactive ...... ation of primary breast cancer

@nl

prefLabel

Extreme loss of immunoreactive ...... ation of primary breast cancer

@ast

Extreme loss of immunoreactive ...... ation of primary breast cancer

@en

Extreme loss of immunoreactive ...... ation of primary breast cancer

@nl

P1433

Q34989083-8A3928B6-745E-40C1-B98D-DE1CAF35B5EC

P1476

Q34989083-82AF5919-3135-4CA3-9FEA-D21249EFAECB

P2093

Q34989083-0C3E0BAA-CEAA-4854-B120-6E5E05E6F8B2

Q34989083-2E6F1E96-C2DA-4D63-AF3D-0AF6AC5CBC9F

Q34989083-35E02F15-07BA-405A-AB11-727F7C8A7D51

Q34989083-3CFC5CFC-81C9-486E-A91D-0C9ED8D524D5

Q34989083-48FD8C0B-2DDE-46A2-97F9-8D128A87917F

Q34989083-7084DED2-C0AF-461D-ADE4-2922652B2F51

Q34989083-803D2FF7-6D76-469E-AE18-EAAEEB424D96

Q34989083-A28079D7-8955-4CEC-B68F-03A0D382A3BE

Q34989083-A60B43DE-F54A-4ECC-8338-C4A45A0BE98B

P2860

Q34989083-0DCE9290-B2D1-43B3-9A4F-BA571A38D0AB

Q34989083-0FD54FC7-3EF4-4E29-A5CD-C80C9D64FF7A

Q34989083-1F3F3BBA-D15C-41C0-A14D-9E2643C852C9

Q34989083-36AEB4B4-7D87-42F9-8C1A-BC6168919166

Q34989083-501E22A5-C47D-4533-9BEB-FD79E5CB3ABA

Q34989083-5705105B-1974-4B14-8EFB-9A55C85D98AB

Q34989083-73750BC5-B361-4413-A89E-441CC30164EA

Q34989083-816B9741-81E2-4C36-8FA3-05D202887483

Q34989083-8C8CEA8C-4417-468A-AF32-6943BC82C18E

Q34989083-954C3B6F-0ECA-4A57-97F5-D65B89020B21

P2888

Q34989083-8144A66B-186D-45F5-87FE-5C41EA6C14E5

P304

Q34989083-C2C2F962-CCF4-45FF-8677-597DB9757518

P31

Q34989083-C198268A-CB8A-4008-B612-C122D7CD2C64

P356

Q34989083-76B72FDE-0E92-49E1-95E4-1AB7FC3661A3

P433

Q34989083-10AD8772-B0F2-441C-B565-2FE480E2503B

P478

Q34989083-FA4DD72A-61DA-40A6-97AB-8C5B12F96E5C

P50

Q34989083-A20D7501-995A-4EFA-9CD5-212D74D58B0F

P577

Q34989083-3A46B682-1088-4458-BB35-3DD050C75EF5

P5875

Q34989083-C6396FF0-35F6-411B-9595-AF0BF65464A4

P6179

Q34989083-783C0E7A-5338-4E3A-88DB-F5BF71E035D9

P698

Q34989083-65AD777A-0AE2-433B-B398-9DAC4ED309B9

P932

Q34989083-F813287A-A3D1-4BAF-9B14-B7567E6A8D1C

P356

P1433

Breast Cancer Research

P1476

Extreme loss of immunoreactive ...... ation of primary breast cancer

@en

P2093

Ashutosh Nerurkar

http://www.w3.org/2001/XMLSchema#string

Fiona A Macneill

http://www.w3.org/2001/XMLSchema#string

Ian E Smith

http://www.w3.org/2001/XMLSchema#string

Isabel F Pinhel

http://www.w3.org/2001/XMLSchema#string

Janine Salter

http://www.w3.org/2001/XMLSchema#string

Margaret J Hills

http://www.w3.org/2001/XMLSchema#string

Peter Osin

http://www.w3.org/2001/XMLSchema#string

Roger A'hern

http://www.w3.org/2001/XMLSchema#string

Simone Detre

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of biospecimens handling on biomarker research in breast cancer

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

Preoperative models to evaluate endocrine strategies for breast cancer.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

P2888

P304

R76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2719

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47335408

http://www.w3.org/2001/XMLSchema#string

P6179

1037594226

http://www.w3.org/2001/XMLSchema#string

P698

20920193

http://www.w3.org/2001/XMLSchema#string

P932

3096968

http://www.w3.org/2001/XMLSchema#string